Glucose
Insulin use, older age raise risk for clinically significant nocturnal hypoglycemia
Insulin use, older age, lower fasting glucose and lower estimated glomerular filtration rate are associated with increased odds for clinically significant nocturnal hypoglycemia in older adults with type 2 diabetes, according to study data.
Rising waist sizes and glucose levels, but metabolic syndrome rate stable among US youths
The metabolic syndrome rate among U.S. youths remained at slightly more than 4% over 20 years, but prevalence increased of large waist circumference and high glucose level, according to results published in JAMA Pediatrics.
Time-restricted eating decreases glucose, improves time in range in type 2 diabetes
Adults with type 2 diabetes had lower fasting glucose and increased time in range with a time-restricted eating window of 10 hours compared with an eating window of 14 hours or longer, according to study data.
‘Simple and economic’ tool: Triglyceride glucose index predicts HFpEF in hypertension
The triglyceride glucose index, a novel marker of insulin resistance, strongly correlates with the occurrence of HF with preserved ejection fraction in adults with hypertension, according to an analysis of electronic medical records data.
High skin autofluorescence, dramatic HbA1c decline increase CV risk in type 2 diabetes
Hospitalized adults with type 2 diabetes have a higher risk for future cardiovascular events with a dramatic decline in HbA1c coupled with long-term high glucose levels as measured by skin autofluorescence, according to study data.
GH levels higher for postmenopausal women vs. men with controlled acromegaly
Among adults with controlled acromegaly, postmenopausal women had higher growth hormone levels than men despite similar insulin-like growth factor I levels, according to study data.
Dasiglucagon lowers IV glucose needed for infants with congenital hyperinsulinism
Dasiglucagon lowers the amount of IV glucose required by more than 50% for infants with congenital hyperinsulinism, according to top-line results from a phase 3 clinical trial.
FDA approves tirzepatide, first dual incretin agonist for type 2 diabetes
The FDA announced it approved the injectable dual incretin agonist tirzepatide to improve glucose response in adults with type 2 diabetes in addition to diet and exercise.
VIDEO: Innovations in diabetes management
CHICAGO — In this video, Rajesh K. Garg, MD, the director of the Comprehensive Diabetes Center at the University of Miami Miller School of Medicine, discusses three evolving areas in diabetes management: glucose goals, treatment and devices.
Addition of empagliflozin improves daytime glucose in type 1 diabetes
Empagliflozin added to automated insulin delivery or predictive low-glucose suspend systems significantly benefited daytime glucose levels for people with type 1 diabetes, with no extra hypoglycemia risk, according to new data.